الصفحة الرئيسية>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>Iberdomide

Iberdomide (Synonyms: CC-220)

رقم الكتالوجGC19195

Iberdomide (CC-220) عبارة عن مُعدِّل ligase cereblon (CRBN) نشط شفهيًا وقويًا (CELMoD) مع IC 50 ~ 150 نانومتر لتقارب ربط cereblon

Products are for research use only. Not for human use. We do not sell to patients.

Iberdomide التركيب الكيميائي

Cas No.: 1323403-33-3

الحجم السعر المخزون الكميّة
2mg
66٫00
متوفر
5mg
104٫00
متوفر
10mg
171٫00
متوفر
25mg
348٫00
متوفر
50mg
549٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Iberdomide (CC-220) is a cereblon modulator with an IC50 of 60 nM.

Lenalidomide and pomalidomide, targeting cereblon, are immunomodulatory drugs that are clinically effective in the treatment of cancer, including newly diagnosed and relapsed multiple myeloma. Iberdomide contains a glutarimide ring that binds in the try-tryptophan pocket of cereblon and an isoindolinone ring that can interact with both cereblon and substrates. Treatment with Iberdomide results in the loss of Ikaros and Aiolos protein levels with EC50s of 1 nM and 0.5 nM [1].

Iberdomide (CC-220) is currently in phase 2 clinical trials for the treatment of systematic lupus erythematosus (SLE) and phase 1b/2a clinical trials for relapsed and refractory multiple myeloma (MM)[1].

References:
[1]. Matyskiela ME, et al. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos. J Med Chem. 2017 Apr 20.

مراجعات

Review for Iberdomide

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Iberdomide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.